Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic (CKM) Syndrome

被引:1
作者
Claudel, Sophie E. [1 ]
Schmidt, Insa M. [2 ]
Waikar, Sushrut S. [2 ]
Verma, Ashish [2 ]
机构
[1] Boston Med Ctr, Dept Med, Boston, MA USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Dept Med, Sect Nephrol, Boston, MA 02215 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年
关键词
cardiovascular disease; CKD; diabetes mellitus; epidemiology and outcomes; mortality risk; US ADULTS; OBESITY; EVENTS; STATEMENT; DISEASE; TRENDS;
D O I
10.1681/ASN.0000000637
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Key PointsCardiovascular-kidney-metabolic (CKM) syndrome stages 1-4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults.Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation.CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality.BackgroundIt is imperative to critically evaluate the prognostic implications of cardiovascular-kidney-metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period.MethodsThis was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999-2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula.ResultsOver a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months.ConclusionsOur findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Association of cardiovascular-kidney-metabolic health and apolipoprotein E4 genotype with risk of dementia and mortality
    Huang, Xinghe
    Liang, Jie
    Zhang, Junyu
    Fu, Jiayi
    Chen, Yige
    Xie, Wuxiang
    Zheng, Fanfan
    JOURNAL OF ALZHEIMERS DISEASE, 2025, : 1270 - 1280
  • [32] Impact of DNA-Methylation Age Acceleration on Long-Term Mortality Among US Adults With Cardiovascular-Kidney-Metabolic Syndrome
    Wu, Shuang
    Zhu, Jun
    Lyu, Siqi
    Wang, Juan
    Shao, Xinghui
    Zhang, Han
    Zhong, Ziyi
    Liu, Hongyu
    Zheng, Lihui
    Chen, Yang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (07):
  • [33] Atherogenic index of plasma and cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stage 1 to 3: a longitudinal study
    Zhang, Yu
    Song, Yue
    Lu, Yinfei
    Liu, Tao
    Yin, Ping
    FRONTIERS IN ENDOCRINOLOGY, 2025, 16
  • [34] Gender Disparities in the Association Between EducationalAttainment and Cardiovascular-Kidney-Metabolic Syndrome:Cross-Sectional Study
    Ding, Yi
    Wu, Xianglin
    Cao, Qiuyu
    Huang, Jiaojiao
    Xu, Xiaoli
    Jiang, Youjin
    Huo, Yanan
    Wan, Qin
    Qin, Yingfen
    Hu, Ruying
    Shi, Lixin
    Su, Qing
    Yu, Xuefeng
    Yan, Li
    Qin, Guijun
    Tang, Xulei
    Chen, Gang
    Xu, Min
    Wang, Tiange
    Zhao, Zhiyun
    Gao, Zhengnan
    Wang, Guixia
    Shen, Feixia
    Luo, Zuojie
    Chen, Li
    Li, Qiang
    Ye, Zhen
    Zhang, Yinfei
    Liu, Chao
    Wang, Youmin
    Yang, Tao
    Deng, Huacong
    Chen, Lulu
    Zeng, Tianshu
    Zhao, Jiajun
    Mu, Yiming
    Wu, Shengli
    Chen, Yuhong
    Lu, Jieli
    Wang, Weiqing
    Ning, Guang
    Xu, Yu
    Bi, Yufang
    Li, Mian
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2024, 10
  • [35] Role of Ectopic Olfactory Receptors in the Regulation of the Cardiovascular-Kidney-Metabolic Axis
    Beito, Mitchell R.
    Ashraf, Sadia
    Odogwu, Dorcas
    Harmancey, Romain
    LIFE-BASEL, 2024, 14 (05):
  • [36] Cardiovascular-Kidney-Metabolic Health Syndrome: What Does the American Heart Association Framework Mean for Nephrology?
    Bansal, Nisha
    Weiner, Daniel
    Sarnak, Mark
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (05): : 649 - 652
  • [37] Amino Acids during Pregnancy and Offspring Cardiovascular-Kidney-Metabolic Health
    Tain, You-Lin
    Hsu, Chien-Ning
    NUTRIENTS, 2024, 16 (09)
  • [38] On the Frontlines of Cardiovascular-Kidney-Metabolic Syndrome: A Review of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Cardiovascular and Kidney Health
    Salama, Lavinia
    Sinn, Levi
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2025,
  • [39] Comparison of triglyceride glucose index and modified triglyceride glucose indices in predicting cardiovascular diseases incidence among populations with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study
    Hong, Jianan
    Zhang, Ruiying
    Tang, Haoxian
    Wu, Shiwan
    Chen, Yequn
    Tan, Xuerui
    CARDIOVASCULAR DIABETOLOGY, 2025, 24 (01)
  • [40] Inverse Relationship Between Serum Carotenoid Levels and Cardiovascular-Kidney-Metabolic Syndrome Among the General Adult Population
    Chen, Mengli
    Cai, Shuyue
    Jia, Qinfeng
    Suo, Yifang
    Tang, Yuan
    Shi, Yanping
    Zhu, Xu
    Zhang, Haifeng
    JOURNAL OF DIABETES, 2025, 17 (02)